Mutual of America Capital Management LLC grew its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 29.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,346 shares of the biopharmaceutical company’s stock after buying an additional 8,600 shares during the quarter. Mutual of America Capital Management LLC owned 0.10% of Sage Therapeutics worth $2,327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SAGE. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares during the period. Turner Investments LLC bought a new position in shares of Sage Therapeutics during the 2nd quarter valued at $159,000. Dubuque Bank & Trust Co. bought a new position in shares of Sage Therapeutics during the 2nd quarter valued at $167,000. Canada Pension Plan Investment Board bought a new position in shares of Sage Therapeutics during the 2nd quarter valued at $175,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Sage Therapeutics during the 2nd quarter valued at $202,000.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://theolympiareport.com/2017/10/31/sage-therapeutics-inc-sage-shares-bought-by-mutual-of-america-capital-management-llc.html.

Sage Therapeutics, Inc. (NASDAQ SAGE) opened at 63.36 on Tuesday. The company’s market capitalization is $2.37 billion. Sage Therapeutics, Inc. has a one year low of $38.30 and a one year high of $90.80. The company has a 50-day moving average price of $64.26 and a 200-day moving average price of $73.78.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the prior year, the business posted ($1.08) EPS. Analysts expect that Sage Therapeutics, Inc. will post ($7.40) earnings per share for the current fiscal year.

Several research firms have recently weighed in on SAGE. Canaccord Genuity lowered their price target on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Stifel Nicolaus began coverage on Sage Therapeutics in a report on Wednesday, August 9th. They set a “buy” rating and a $104.00 price target on the stock. Needham & Company LLC set a $95.00 price target on Sage Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. BidaskClub cut Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Cowen and Company lowered their price target on Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $86.50.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.